Abstract
Although essential guidance to cover the photostability testing of pharmaceuticals for manufacturing and storage is well-established, there continues to be a significant gap in guidance regarding testing to support the effective administration of photosensitive drug products. Continuing from Part 1, (Baertschi SW, Clapham D, Foti C, Jansen PJ, Kristensen S, Reed RA, Templeton AC, Tønnesen HH. 2013. J Pharm Sci 102:3888-3899) where the focus was drug products administered by injection, this commentary proposes guidance for testing topical drug products in order to support administration. As with the previous commentary, the approach taken is to examine "worst case" photoexposure scenarios in comparison with ICH testing conditions to provide practical guidance for the safe and effective administration of photosensitive topical drug products.
Author supplied keywords
Cite
CITATION STYLE
Baertschi, S. W., Clapham, D., Foti, C., Kleinman, M. H., Kristensen, S., Reed, R. A., … Tønnesen, H. H. (2015, September 1). Implications of In-Use Photostability: Proposed Guidance for Photostability Testing and Labeling to Support the Administration of Photosensitive Pharmaceutical Products, Part 2: Topical Drug Product. Journal of Pharmaceutical Sciences. John Wiley and Sons Inc. https://doi.org/10.1002/jps.24396
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.